LATEST TWEETS - CURATED BY HASH FINANCE

William Blair Reaffirms Buy Rating for Rocket Pharmaceuticals $RCKT https://t.co/8XzH7BoXAo #stocks
TREND REVERSAL UP ALERT: $RCKT Rocket Pharmaceuticals, Inc 📈 TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room
William Blair Reiterates “Buy” Rating for Rocket Pharmaceuticals $RCKT https://t.co/b81P3AJ686
$RCKT (+0.0% pre) Rocket Pharma's mid-stage FANCOLEN-II study of RP-L102 cleared in Spain - SA https://t.co/Fgr1dPLBuA
$RCKT - Rocket Pharma's mid-stage FANCOLEN-II study of RP-L102 cleared in Spain https://t.co/X7BF3Z8uox
-$0.50 EPS Expected for Rocket Pharmaceuticals Inc $RCKT This Quarter https://t.co/f49nFWtZh9
Brokerages Expect Rocket Pharmaceuticals Inc $RCKT Will Announce Earnings of -$0.50 Per Share https://t.co/7M59JTSUFT
Q3 2019 EPS Estimates for Rocket Pharmaceuticals Inc $RCKT Reduced by Oppenheimer https://t.co/crVufbZdiv
Q3 2019 EPS Estimates for Rocket Pharmaceuticals Inc $RCKT Reduced by Oppenheimer https://t.co/IfNJGZUccd
Rocket Pharmaceuticals $RCKT Upgraded to Buy by Zacks Investment Research https://t.co/EMqh5ZRqOW
Zacks: Brokerages Anticipate Rocket Pharmaceuticals Inc $RCKT to Post -$0.50 Earnings Per Share https://t.co/7Q6cpCA1LX
Zacks: Brokerages Anticipate Rocket Pharmaceuticals Inc $RCKT to Post -$0.50 Earnings Per Share https://t.co/9pYLWaTt9o #stocks
Zacks: Brokerages Anticipate Rocket Pharmaceuticals Inc $RCKT to Post -$0.50 Earnings Per Share https://t.co/KoIEbkEc38
Zacks Investment Research Upgrades Rocket Pharmaceuticals $RCKT to “Buy” https://t.co/S3FURjZ2dQ
Zacks Investment Research Upgrades Rocket Pharmaceuticals $RCKT to “Buy” https://t.co/YFtz0tsjrQ
Rocket Pharmaceuticals $RCKT Upgraded at Zacks Investment Research https://t.co/6pphveNglG
Rocket Pharmaceuticals $RCKT PT Lowered to $37.00 https://t.co/VroWD5EhTM
Rocket Pharmaceuticals $RCKT PT Lowered to $37.00 https://t.co/9RrtZnWuzz
Oppenheimer Lowers Rocket Pharmaceuticals Q3 2019 Earnings Estimates to ($0.75) EPS (Previously ($0.74)).… https://t.co/pUZPdC3jqE
Ecor1 2Q 13F: $XNCR +277,128 (Now #2 pos) $FGEN +1,343,403 (+797%, sold pos prior to data, bought after data)… https://t.co/LVzuFNT4ZZ
$rckt must be tapping their mixed shelf, now below $11 hitting 52w lows https://t.co/Tj4WZ43GCc
Rocket Pharmaceuticals $RCKT Rating Increased to Buy at Zacks Investment Research https://t.co/nLZgMd5mDr
Rocket Pharmaceuticals $RCKT Rating Increased to Buy at Zacks Investment Research https://t.co/F0xLp4DNqZ